You are here

Article Text

Article menu
Download PDFPDF
Brief report
Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin)
  1. Catherine Rhodes,
  2. John Harris,
  3. John Sulston,
  4. Catherine Spanswick
  1. University of Manchester, Institute for Science, Ethics and Innovation, Manchester, UK
  1. Correspondence to Dr Catherine Rhodes, Institute for Science, Ethics and Innovation, School of Law, Williamson Building, University of Manchester, Oxford Road, Manchester, UK; catherine.rhodes-2{at}manchester.ac.uk

Abstract

There are several good reasons for the UK Department of Health to recommend the appraisal of bevacizumab for the treatment of eye conditions by the National Institute for Health and Clinical Excellence. These reasons will extend to other drugs when similar situations arise in the future.

  • Bioethics
  • chemical and biological weapons
  • drugs and drug industry
  • international affairs

http://dx.doi.org/10.1136/medethics-2011-100032

Statistics from Altmetric.com

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    © 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

    Other content recommended for you